Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections

Laboratoires Pierre Fabre erhält die Zulassung der Europäischen Kommission für BRAFTOVI® (Encorafenib) in Kombination mit Cetuximab und FOLFOX (Fluorouracil, Leucovorin und Oxaliplatin) zur Erstlinienbehandlung erwachsener Patienten mit BRAFV600E-mutiertem, em metastasiertem Kolorektalkarzinom (mCRC)

Raymond Rodriguez-Torres Appointed First Ascent Biomedical New President to Scale Functional Precision Oncology

Ellison Medical Institute and UniQuest enter exclusive license to advance novel prostate cancer therapy toward first-in-human studies

BARBRI Acquires Lega to Accelerate Practical AI Fluency Across the Legal Profession, Bringing Experiential AI Learning to Law Students and Legal Professionals

Armstrong Lee & Baker LLP Offering Free Uber Rides in Houston for a Safe 4th of July!

Glancy Prongay Wolke & Rotter LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Eagle Pharmaceuticals, Inc. Common Stock

SKS EXPANDS TECHNICUREAN LIVING WITH NEW LUXURY DESIGN DESTINATION

Les Laboratoires Pierre Fabre ont reçu l'approbation de la Commission européenne pour BRAFTOVI® (encorafenib) en association avec le cetuximab et FOLFOX (fluorouracile, leucovorine et oxaliplatine) comme traitement de première ligne chez les patients adultes atteints d'un cancer colorectal métastatique (CCRm) avec mutation BRAFV600E

Laboratoires Pierre Fabre riceve l'approvazione della Commissione Europea per BRAFTOVI® (encorafenib) in combinazione con cetuximab e FOLFOX (fluorouracile, leucovorin e oxaliplatino) per il trattamento di prima linea di pazienti adulti affetti da carcinoma colorettale metastatico (mCRC) con mutazione BRAFV600E

TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million

TrueLab Biopharmaceutical anuncia un acuerdo de licencia con Bionyra Pharma

SoCalGas Employees Volunteer Across Southern California, Providing 1,100+ Volunteer Hours to Help Families Access Essential Resources

Michael Pillsbury Joins American Global Strategies as a Senior Advisor

CH4 Natural Solutions Corporation Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing June 22, 2026

Magaya and Adelante SCM Release New Research on How Leading Logistics Service Providers Are Using Technology to Gain a Competitive Edge

PNC Completes FirstBank Customer Conversion

Castor Maritime Inc. Announces Vessel Acquisition

Moldova Digital Summit 2026 : la commissaire européenne Marta Kos félicite la Moldavie, qu'elle qualifie de « réussite numérique »

Gary Payton II Named Chief Athletic Ambassador of Valor

World Finance announces the release of its Summer 2026 edition

TransMedia Group to Amplify the Transformative Story Behind She Sings® and Its Creator Rebecca Magnuson

DaVinci Commerce Announces Agentic BrandStore Enterprise: End-To-End Agentic Commerce From Discovery To Purchase Across AI platforms

Canyon Partners Closes €400 Million European CLO

Tredence Acquires KMK Consulting to Accelerate Healthcare and Life Sciences Growth

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Guardz Wins Best Managed Detection and Response (MDR) in The Hacker News 2026 Cybersecurity Stars Awards

Edible Garden's Pickle Party™ Named "Overall Plant-Based Snack Product of the Year" in 2026 Mindful Awards Program

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors